Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19
Topline data for two studies of KB109 are expected in the first quarter of 2021LEXINGTON, Mass., Jan. 04, 2021 (GLOBE...